Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00509782 | Phase I Trial of ZIO-101 in Patients With Solid Tumors | PHASE1 | COMPLETED | 47 | — | — | May 1, 2005 | Apr 1, 2008 | Aug 1, 2012 | 1 | United States |
| NCT00591396 | A Phase I Trial of ZIO-101 in Solid Tumors | PHASE1 | COMPLETED | 40 | — | — | Jul 1, 2005 | Jul 1, 2008 | Jul 19, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| ZIO-101 | EXPERIMENTAL | - |
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ZIO-101 | DRUG | Starting Dose 78 mg/m\^2 intravenously daily for 5 consecutive days repeated every 4 weeks. |
| ZIO-101 (Darinaparsin) | DRUG | Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months |
Inclusion Criteria: 1. Patients with histological confirmation solid malignancy refractory to conventional standard therapies for their condition. 2. Eligible subjects MUST have at least one measurable lesion as defined by RECIST guidelines. If the measurable disease is restricted to a solitary les...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |